ADMA Biologics, Inc. (ADMA:NASDAQ) closed at $11.07 on October 26, 2026, up 3.60% on the day. The stock trades 45.9% below its 52-week high of $20.46 and 53.5% above its 52-week low of $7.21. Over the past year, it lost 29.1%. ADMA Biologics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 24, 2025, ADMA closed higher on 122 days (48%). Its best day was March 27, 2026 (+11.58%) and its worst was March 24, 2026 (-16.63%). The stock moved 10% or more in a single session 5 times.
ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.
Find more stocks like ADMA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.